Pharmaceutical, Vaccine, mRNA and API Manufacturing GMP HVAC Duct Guide — TGA GMP, PIC/S PE 009, EU GMP Annex 1, ISO 14644

Why pharmaceutical HVAC sits at the apex of the GMP infrastructure stack

A pharmaceutical manufacturing facility licensed by the Therapeutic Goods Administration is, in engineering terms, an HVAC platform with manufacturing equipment installed inside it. The cleanroom envelope, the pressure cascade, the HEPA terminal supply, the segregated exhaust paths, the BMS that records every parameter across every batch — these are the engineering systems that the TGA inspector audits against, the systems that the PIC/S auditor reviews, the systems that a US FDA pre-approval inspector examines first when the facility seeks to export. Get the HVAC right and the rest of the GMP system has a chance. Get the HVAC wrong and the entire facility is a non-conformance event waiting to be written up.

The discipline is unusually demanding. An aseptic fill-finish suite producing a sterile injectable holds a Grade A critical zone at ISO 14644 Class 5 inside an isolator with unidirectional airflow at 0.36 to 0.54 metres per second, surrounded by a Grade B background at 40 to 60 air changes per hour, surrounded by Grade C support areas at 20 to 40 ACH, each held at a positive pressure differential of 10 to 15 Pa to the next-lower grade, with the entire pressure cascade continuously monitored on a GxP-validated building management system. A BSL-3 vaccine manufacturing suite producing live attenuated or viral-vector vaccines holds the room at minus 25 Pa to the corridor, with single-pass once-through ventilation, HEPA H14 exhaust through gas-tight bag-in bag-out filter housings, and a 30-second tolerance on loss of negative pressure before the facility is in a containment failure event. An API synthesis hall handling solvent inventories at the kilogram-to-tonne scale operates under AS/NZS 60079 Zone 1 and Zone 2 hazardous area classification with intrinsically-safe instrumentation throughout, explosion-relief panels per NFPA 68, and a regenerative thermal oxidiser on the solvent vapour exhaust path. A vaporised hydrogen peroxide decontamination cycle drives H2O2 vapour to 1,000 to 2,000 ppm peak inside a sealed cleanroom, then aerates back below the Safe Work Australia 1 ppm 8-hour exposure limit before staff re-entry. Each of these design problems is solved by a ductwork specification, a fabrication standard and a commissioning protocol — not by software, not by documentation, not by training, but by metal and welds and joints and seals.

This guide is the design reference SBKJ engineers in Box Hill North Victoria use when briefed by mechanical consultants, GMP project managers, validation engineers and fit-out contractors fabricating ductwork for major Australian pharmaceutical, vaccine, biotech and API manufacturing scopes. It walks through the regulatory framework, zone-by-zone HVAC specification, materials selection, fabrication and commissioning sequence, and verification protocol. It is not a substitute for a registered mechanical engineering design, a TGA GMP licence consultation or a qualified QA/validation engineer.

The Australian regulatory and GMP standards stack

Pharmaceutical HVAC in Australia is governed by a tightly-layered stack of mandatory standards, harmonised international codes, ICH-derived guidelines, and Australian Standards. No single document gives the complete picture. The stack we work with on every project, in priority order, is set out below.

TGA Manufacturing Code and PIC/S Guide to GMP PE 009

The Therapeutic Goods Administration is the Australian regulator. A facility manufacturing therapeutic goods (medicines, biologics, vaccines, blood products, certain medical devices) must hold a TGA manufacturing licence and demonstrate compliance with the TGA Manufacturing Code. The substance of the code is the Pharmaceutical Inspection Co-operation Scheme (PIC/S) Guide to GMP, currently PE 009 in its most recent revision. Australia is a founding PIC/S member; PIC/S harmonises GMP requirements across more than 50 participating regulators including TGA, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency, Health Canada, Singapore HSA, Japan PMDA and (since 2018) the US Food and Drug Administration. A PIC/S GMP compliant facility satisfies TGA, EMA and most other participating regulators in substance.

EU GMP Annex 1 (revised 2022)

EU GMP Annex 1 is the sterile manufacturing standard. The 2022 revision (fully effective August 2023) substantially tightened the requirements for contamination control, particularly in aseptic processing. Key elements: Grade A unidirectional airflow at 0.36 to 0.54 m/s at the working position, formally measured and documented; Grade A criticality defined by the product contact pathway rather than the room classification alone; explicit requirements for the Contamination Control Strategy (CCS) as a documented systematic approach; isolator and RABS preferred over conventional open-room aseptic processing; pre-use post-sterilisation integrity testing (PUPSIT) for sterilising-grade filters; and tightened requirements for VHP cycle validation and aeration verification. Annex 1 is incorporated into PIC/S PE 009 in substance — an Australian TGA-licensed facility producing a sterile injectable must demonstrate Annex 1 compliance, in addition to whatever the TGA inspector explicitly references.

EU GMP Annex 11 and 21 CFR Part 11

EU GMP Annex 11 (computerised systems) and US FDA 21 CFR Part 11 (electronic records and electronic signatures) govern the GxP validation of every computerised system inside the facility, including the BMS that monitors HVAC. The BMS is a GxP system: data integrity, audit trail, access control, system validation through DQ/IQ/OQ/PQ, change control, and periodic review are all GxP requirements. A BMS that monitors a Grade A/B/C/D cleanroom is therefore subject to the same validation discipline as a process control system or a laboratory information management system.

US FDA 21 CFR 210/211 and 21 CFR 600

For facilities exporting to the US (a sizeable share of Australian pharmaceutical and biotech production), the US FDA Code of Federal Regulations applies. 21 CFR 210 and 211 cover current Good Manufacturing Practice for finished pharmaceuticals (cGMP). 21 CFR 600 covers biological products including vaccines. The substance is closely aligned with EU GMP Annex 1 and PIC/S PE 009 but the FDA inspection protocol and the language of the regulations differ. CSL Limited and Moderna Australia both export to the US and operate facilities qualified under both PIC/S and FDA regimes.

ICH Q7 (API), Q9 (QRM) and Q1A (Stability)

The International Council for Harmonisation (ICH) issues guidelines that bridge regional regulatory frameworks. ICH Q7 covers Good Manufacturing Practice for Active Pharmaceutical Ingredients — the API synthesis suite, the upstream of every pharmaceutical formulation. ICH Q9 covers Quality Risk Management — the framework that justifies design choices including HVAC classifications, ACH minimums, and pressure differentials. ICH Q1A covers stability testing programmes — driving the design of stability chamber rooms at 25/60, 30/65, 40/75 and 5 degrees Celsius. WHO GMP Annex 5 supplements ICH for non-sterile dosage form manufacturing HVAC.

ISO 14644 and ISO 14698

ISO 14644 is the international cleanroom classification standard. ISO 14644-1 sets the particle count limits for each ISO class. ISO 14644-2 covers monitoring. ISO 14644-3 covers test methods including velocity measurement, recovery time and filter integrity. The mapping between EU GMP grades and ISO classes: Grade A is ISO Class 5 (in operation and at rest); Grade B is ISO Class 5 at rest and ISO Class 7 in operation; Grade C is ISO Class 6 or 7 at rest and ISO Class 8 in operation; Grade D is ISO Class 7 or 8 at rest and ISO Class 9 or unclassified in operation. ISO 14698 covers biocontamination control — environmental monitoring with settle plates, surface contact plates and active air sampling, with action and alert limits set per the Contamination Control Strategy.

ASHRAE Applications Chapter 18 and AS 1668.2

ASHRAE Handbook — Applications, Chapter 18 (Clean Spaces) is the engineering reference for cleanroom HVAC design — ACH calculations, supply diffuser selection, return strategy, filter loading allowance, room recovery time. Widely cited in Australian briefs as the supplementary engineering reference where AS 1668.2 is silent. AS 1668.2 is the National Construction Code's referenced mechanical ventilation standard, the legal floor for Australian building HVAC. For a pharmaceutical facility, AS 1668.2 is necessary but never sufficient — EU GMP Annex 1 expectations sit substantially above AS 1668.2 on every parameter, and the design meets the higher of the two.

AS 4254, AS 1530.4 and AS 1851

AS 4254 sets ductwork construction and leakage classification. Most pharmaceutical work falls into Class B (medium pressure, up to 750 Pa) for cleanroom supply and Class C (high pressure, up to 1,500 Pa) for BSL-3 exhaust, API solvent exhaust, lyophiliser vacuum exhaust and radiopharmaceutical hot cell exhaust. AS 1530.4 covers fire-rated construction including fire and smoke dampers; AS 1851 covers the maintenance regime. A pharmaceutical facility typically sits within a building's smoke compartment hierarchy with each major cleanroom or production zone often forming its own fire compartment.

AS/NZS 60079 hazardous area, AS 1940 flammable liquids

API synthesis halls, mRNA LNP formulation suites, solvent dispensing rooms and solvent recovery operations handle flammable liquid inventories that exceed the AS 1940 thresholds for hazardous area classification under AS/NZS 60079. Zone 0 (continuous flammable atmosphere), Zone 1 (intermittent flammable atmosphere), Zone 2 (rare or short-duration flammable atmosphere) define the equipment selection and ventilation design. ATEX-rated fans, dampers and instrumentation throughout the classified zone; intrinsically-safe BMS sensors; explosion-relief panels sized per NFPA 68; dilution ventilation calculated to hold the airborne concentration below 25 percent of the lower flammable limit (LFL).

AS/NZS 2243 microbiology and AS/NZS 2982 lab design

AS/NZS 2243.3 covers microbiological safety and contains the Australian Biosafety Level (BSL) framework — BSL-1 through BSL-4 — aligned with the WHO Laboratory Biosafety Manual. AS/NZS 2243 series covers broader laboratory safety. AS/NZS 2982 covers laboratory design. Quality Control microbiology laboratories inside a pharmaceutical facility operate under BSL-2 with Class II A2 biosafety cabinets; vaccine seed and viral vector production suites operate under BSL-3 with the engineering controls set out in this guide.

USP <797> and USP <800>

USP <797> (sterile compounding) governs hospital pharmacy compounding of sterile preparations — chemotherapy reconstitution, total parenteral nutrition, eye drops, custom sterile injectables. USP <800> covers hazardous drug handling including chemotherapy — segregated compounding areas with dedicated exhaust to outdoor, biological safety cabinets vented to outdoor through HEPA H14, and pressure cascade reinforcing containment. Hospital pharmacy compounding HVAC is technically a sub-set of pharmaceutical manufacturing HVAC and is dealt with under the broader pharmaceutical framework in this guide.

Safe Work Australia workplace exposure standards

Safe Work Australia workplace exposure standards (WES) govern airborne chemical concentrations in Australian pharmaceutical manufacturing. The HVAC design ensures that ACH and pressure cascade keep airborne exposures well below the WES at routine use. The relevant solvent and chemical WES values across pharmaceutical operations: ethanol 1,000 ppm 8-hour TWA, isopropanol 400 ppm, methanol 200 ppm, acetone 500 ppm, methyl ethyl ketone (MEK) 200 ppm, hexane 50 ppm, ammonia 25 ppm, formaldehyde 1 ppm STEL, hydrogen peroxide 1 ppm 8-hour TWA, peracetic acid 0.4 ppm STEL, ozone 0.1 ppm. Vapour monitors at breathing height with BMS alarming at 50 percent and 100 percent of the WES is the engineering pattern.

The EU GMP Annex 1 pressure cascade and Grade A/B/C/D zone matrix

Every aseptic pharmaceutical design begins from the same starting point: the Grade A/B/C/D zone matrix and the pressure cascade that holds the airflow direction from cleanest to less clean. The cascade is the strongest engineering control in the entire facility and the specification most likely to be misdesigned at concept or to drift in operation.

Grade A — Aseptic critical zone, ISO Class 5 in operation. The product contact zone during fill-finish, lyophiliser loading or aseptic connection. Enclosed inside a closed isolator (Skan SVC, Bosch APR, Optima MultiUse, Stilmas, IMA Life and equivalents) or a Restricted Access Barrier System (RABS). Inside the enclosure: HEPA H14 unidirectional supply at 0.36 to 0.54 m/s at the working position, either no return (closed isolator) or HEPA-filtered exhaust at a defined controlled leak rate (open isolator). Pressure +15 Pa to Grade B background. ISO Class 5 at-rest and in operation by ISO 14644-1 particle counts. Temperature 18 to 22 degrees Celsius, RH 30 to 50 percent.

Grade B — Aseptic background, ISO Class 7 in operation. The sterile gowning area, the area immediately around the isolator or RABS, and the area where Grade A interventions occur. At-rest classification is ISO Class 5 (the same as Grade A) but in-operation drops to ISO Class 7 because operator activity adds particles. Pressure +10 Pa to Grade C. 40 to 60 ACH minimum HEPA H14 terminal supply through non-aspirating ceiling diffusers. Type 316L stainless steel supply and return ductwork throughout. Acoustic NC-45 maximum. Temperature 18 to 22 degrees Celsius, RH 30 to 60 percent. Operator gown is sterilised, head-to-toe coverage including hands (sterile gloves), face (sterile mask and goggles) and feet (sterile overshoes).

Grade C — Preparation and formulation, ISO Class 8 in operation. Solution compounding tanks, primary container (vial and syringe) preparation, lyophiliser loading area, component staging, weighing and dispensing for sterile-product manufacture. Pressure +5 Pa to Grade D. 20 to 40 ACH with HEPA H14 or H13 terminal supply. Type 316L or Type 304 stainless ductwork. Acoustic NC-50 maximum. Temperature 18 to 24 degrees Celsius, RH 30 to 60 percent. Operator gown is a clean gown (laundered to documented specification), head cover, face mask, gloves and overshoes — less stringent than Grade B sterile gowning.

Grade D — Lowest classified grade, ISO Class 9 or unclassified in operation. Bulk pharmaceutical excipient warehousing, packaging materials, secondary packaging operations, weighing and dispensing for non-sterile-product manufacture. Pressure +5 Pa to unclassified corridor. 10 to 20 ACH with HEPA H13 supply. Type 304 stainless or G90 galvanised ductwork acceptable. Acoustic NC-50 maximum. Temperature 18 to 24 degrees Celsius, RH 30 to 65 percent.

Unclassified corridor and support. Ambient pressure. Conventional ducted ventilation to AS 1668.2 minimum. G90 galvanised ductwork acceptable. The unclassified envelope is the bulk of the building — corridors, plant rooms, administrative offices, staff amenities, dispatch and receiving — and the cost-effective base where the GMP-rated cleanroom envelope sits inside it.

The airlock chain at every grade transition

Every transition from one Grade to the next is bridged by an airlock chain — a small intermediate space with interlocked doors at each end that prevents simultaneous open-door connection between Grades. The airlock chain reinforces the pressure cascade during personnel and material flow and acts as a buffer for the inevitable transient pressure excursions when doors open. EU GMP Annex 1 (2022) explicitly endorses interlocked airlock chains as the preferred control. Cascade airlocks (the intermediate space is pressurised between the two adjacent Grades) or sink airlocks (the intermediate space is pressurised lower than both adjacent Grades, useful for moving contaminated material out) are both used depending on flow direction.

Material airlocks are typically larger than personnel airlocks, with pass-through hatches at each end, dwell timers (typically 30 to 90 seconds) that enforce minimum interlock duration regardless of operator behaviour, and HEPA H14 supply that achieves room recovery to classification within the dwell period. The airlock chain HVAC is engineered at the same standard as the Grades it connects — never compromised because the airlock is small.

The aseptic fill-finish suite — isolator and RABS design

The aseptic fill-finish suite is the highest-risk zone in any pharmaceutical facility producing a sterile injectable. The product moves from a closed sterilised primary container through fill, stoppering, capping and visual inspection without contacting the room air. A breach of the sterile boundary at any point is a contamination event that may not be detectable until release testing or, worse, in clinical use. The engineering controls are correspondingly stringent.

Closed isolators

A closed isolator (Skan, Bosch, Optima, Stilmas, IMA Life, Getinge La Calhene and equivalents) is a fully-sealed enclosure that maintains its own GMP-validated environment independent of the surrounding cleanroom. Inside the isolator: HEPA H14 supply through a unidirectional flow ceiling, working position air velocity 0.36 to 0.54 m/s at the working height, recirculated air drawn through return HEPA filtration, vaporised hydrogen peroxide decontamination capability between batches, and gauntlet ports for operator intervention. Pressure inside the isolator is +15 to +50 Pa to the Grade B background. The surrounding cleanroom is Grade B at-rest, dropping to ISO Class 7 in operation, with the room HVAC sized to maintain Grade B even as the isolator vents its return air to the room (open closed isolator) or contains all return air (true closed isolator).

The isolator HVAC interface with the cleanroom HVAC is the design-critical junction. The isolator make-up air comes from the cleanroom HEPA-filtered supply (typically HEPA H14 through a bubble-tight damper that closes during VHP cycles), the isolator exhaust returns to the cleanroom or vents to outdoor through a HEPA H14 exhaust filter and a bubble-tight isolation damper. The dampers themselves are leak-tight to Class 4 (5 cubic centimetres per second per square metre at design pressure) or better — functionally airtight when closed.

Restricted Access Barrier Systems (RABS)

A RABS sits between an open Grade A workstation and a closed isolator. It uses a rigid physical barrier (typically polycarbonate panels with gauntlet glove ports) to separate the operator from the Grade A critical zone, with HEPA H14 unidirectional flow at the working position. Open RABS allows occasional door opening for product transfer; closed RABS does not. RABS is the older configuration and is being progressively replaced by isolators in new-build facilities, though many existing aseptic suites — particularly older fill-finish lines at CSL, GlaxoSmithKline, Sanofi and the contract manufacturers — continue to operate RABS successfully.

HVAC integration for RABS: the Grade B background HVAC supplies the RABS canopy through HEPA H14 terminal filters mounted directly above the working zone, with the canopy maintaining unidirectional flow into the room at the perimeter. The RABS is decontaminated between batches with VHP or alcohol surface disinfection; full bio-decontamination of the surrounding Grade B suite is performed on a documented periodicity (typically weekly or per campaign).

The lyophiliser interface

The lyophiliser (freeze-dryer) is integrated into the aseptic fill-finish line for products that cannot be terminally sterilised in solution — biologics, vaccines, mRNA, peptide drugs and many small-molecule sterile injectables. Vials are filled and partially-stoppered in Grade A inside the isolator or RABS, transferred to the lyophiliser through a sealed transfer chamber that maintains Grade A during transfer, freeze-dried over a 24 to 72 hour cycle, and then the stopper is pushed down inside the lyophiliser chamber under partial vacuum or inert gas. The lyophiliser door at the Grade A side opens into the isolator or RABS Grade A enclosure; the door at the Grade B/C side opens for loading and CIP/SIP access.

HVAC integration: the lyophiliser room body is Grade C with allowance for the heat rejection of the refrigeration plant (30 to 80 kW sensible heat for typical chamber sizes). The vacuum pump exhaust ducts to outdoor through Type 316L stainless steel exhaust with an oil-mist eliminator and a HEPA H14 prefilter. The CIP/SIP cycle (between batches, typically alkaline detergent CIP followed by steam SIP at 121 to 134 degrees Celsius) generates short-duration steam that vents through a dedicated condensate-managed exhaust path with 1:50 minimum slope to a trapped condensate drain.

BSL-3 vaccine manufacturing — the negative-pressure containment suite

Vaccine manufacturing using live attenuated, inactivated or viral-vector platforms (CSL Seqirus influenza vaccine, classical live virus vaccines, adenoviral vector vaccines, lentiviral vector vaccines for gene therapy upstream) handles Risk Group 3 pathogens in production quantities. The suite operates under AS/NZS 2243.3 and the WHO Laboratory Biosafety Manual fourth edition at Biosafety Level 3. The HVAC design is correspondingly the strongest containment engineering in the building.

Pressure cascade and containment

The BSL-3 suite is held at minus 25 Pa minimum relative to the adjacent corridor. Single-pass once-through ventilation is mandatory — no recirculation under any condition, ever. All exhaust is HEPA H14 filtered through gas-tight bag-in bag-out (BIBO) filter housings before discharge to a high-velocity vertical exhaust stack with minimum 12 m/s discharge velocity and minimum 3 metres above roof. The exhaust stack discharges away from intakes and prevailing wind direction.

Loss of negative pressure for more than 30 seconds is a containment failure event. The HVAC design must hold the cascade through every credible operational scenario including door opening, isolator make-up draw, autoclave cycle peak, normal HEPA filter loading, and the failure of one exhaust fan in a parallel pair. N+1 fan redundancy on the exhaust and emergency power that holds the exhaust running through grid loss are mandatory engineering features.

Entry and exit airlock chain

The BSL-3 suite is entered through an airlock chain: outer corridor at ambient pressure, gowning anteroom at minus 5 Pa, full PPE donning area at minus 10 Pa, decontamination shower (where required by the agent risk profile) at minus 15 Pa, and the working suite at minus 25 Pa. The chain reinforces the cascade and provides the bio-decontamination step on exit. Interlocked doors at every transition prevent open-door connection between the working suite and the outer corridor.

Waste kill-step

All solid waste leaving the BSL-3 suite passes through a double-door autoclave at 134 degrees Celsius porous-load steriliser cycle (ISO 17665 compliant). The autoclave door on the BSL-3 side is interlocked to prevent opening if the door on the corridor side is open — one direction at a time, never both. Liquid waste passes through a liquid effluent decontamination system that thermally inactivates at 121 degrees Celsius for a documented dwell time before discharge to trade waste. Both kill-steps are validated to a documented log-reduction (typically 6-log reduction of the target agent or its surrogate).

Exhaust ductwork specification

BSL-3 exhaust ductwork is Type 316L stainless steel, continuously TIG-welded with full SMACNA Seal Class A integrity, leak-tested at 1.5 times maximum operating pressure to Class 6 or better, sized to AS 4254 Class C. The BIBO HEPA filter housing is integral to the suite envelope and is itself bio-decontaminated by VHP or formaldehyde fumigation before filter change-out. The exhaust fan is downstream of the BIBO filter so that the duct between fan and discharge stack operates at slight negative pressure to outdoor — any leak draws ambient air inward rather than allowing biological aerosol outward.

mRNA manufacturing — lipid nanoparticle (LNP) formulation as the design-critical area

mRNA vaccine and therapeutic manufacturing (Moderna Australia Clayton VIC, Pfizer-BioNTech process style, the emerging mRNA capability at multiple Australian biotech sites) splits the process into three HVAC zones with distinct requirements.

Upstream in-vitro transcription

The upstream suite produces mRNA via in-vitro transcription (IVT) of a DNA template using a phage RNA polymerase. The IVT reaction is closed-system at the bench scale and at the bioreactor scale. Process equipment includes plasmid linearisation and purification trains, the IVT reactor, and downstream capping and tailing reactors. HVAC: Grade C cleanroom at 20 to 40 ACH with HEPA H14 supply, +5 Pa to Grade D, Type 316L stainless ductwork. The biological hazard is low (the working organism is a non-replicating recombinant RNA, not a Risk Group 3 pathogen) but GMP grade matters because the product is a parenteral therapeutic.

LNP formulation and the ATEX design challenge

The lipid nanoparticle (LNP) formulation suite is where the mRNA is encapsulated in a lipid nanoparticle that delivers it into cells. The process mixes an aqueous mRNA solution with an ethanol solution of four lipids (ionisable cationic lipid, structural lipid, PEG-lipid, cholesterol) in a controlled mixing device (typically a microfluidic chip or a T-junction mixer). The ethanol fraction is then removed by tangential-flow filtration or dialysis. The process runs at the litre to hundred-litre scale with ethanol inventory at the tens-of-litres to hundreds-of-litres range per batch.

Ethanol vapour above the formulation suite at this inventory size triggers AS/NZS 60079 hazardous area classification. The room is typically Zone 2 (occasional, short-duration flammable atmosphere) under normal operation, with Zone 1 hot-spots at solvent transfer points and at the open mixing device. HVAC design: dilution ventilation sized to hold the airborne ethanol concentration below 25 percent of the lower flammable limit (LFL for ethanol is 3.3 percent vol/vol; design target therefore below 0.825 percent vol/vol = 8,250 ppm; routine operation target below 200 ppm = 20 percent of the Safe Work Australia 1,000 ppm 8-hour TWA). Dedicated solvent vapour exhaust through a recovery condenser (which condenses ethanol and lipids out of the exhaust stream for reuse or compliant disposal) or a regenerative thermal oxidiser (RTO). ATEX-rated fans, dampers and instrumentation throughout the Zone 2 area. Intrinsically-safe BMS sensors.

The LNP formulation suite is therefore engineered as both a Grade C cleanroom (for product protection) and a Zone 2 hazardous area (for personnel and asset protection). The two requirements reinforce each other on most parameters (high ACH suits both) but conflict on others (cleanroom diffusers are typically not ATEX-rated; recirculation suits cleanroom thermal management but not flammable atmosphere control). Resolving the conflict is the design engineer's task on every mRNA facility.

Downstream aseptic fill-finish

The downstream fill-finish suite is conventional sterile aseptic at Grade A inside an isolator or RABS with Grade B background, identical in HVAC pattern to any biologics fill-finish line. The mRNA-LNP drug product is filled into vials or pre-filled syringes, optionally lyophilised, capped, inspected and labelled. The product is then held at minus 80 degrees Celsius in ultra-low freezer storage or at minus 150 degrees Celsius in cryogenic vapour-phase storage until distribution.

Cell and gene therapy (CGT) manufacturing

Cell and gene therapy manufacturing — including Chimeric Antigen Receptor T-cell (CAR-T) therapies, mesenchymal stem cell products (Mesoblast), gene-modified autologous cell therapies (Cynata), viral vector production for in-vivo gene therapy (Avita Medical for skin and others), and emerging allogeneic cell therapy platforms — sits in a hybrid space between conventional pharmaceutical manufacturing and biological research. The unit-of-product is often a single patient dose at small batch scale, the manufacturing process is heavily manual or single-use automated, and the GMP framework is evolving as the sector matures.

Cleanroom envelope and biosafety cabinet integration

CGT manufacturing sits within a BSL-2 cleanroom envelope. Open processing operations (cell counting, microscopy, sample inoculation, manual interventions) occur inside a Class II Type A2 biosafety cabinet (BSC) within the Grade B or Grade C cleanroom. Closed processing operations (cell culture in single-use bioreactor bags, sterile-welded tubing transfers, automated cell processing systems like Miltenyi CliniMACS Prodigy or Lonza Cocoon) occur in single-use bioreactor systems that maintain the sterile boundary without requiring an open Grade A environment.

The BSC is the design-critical equipment. A Class II Type A2 BSC vents 30 percent of cabinet airflow to outdoor through HEPA H14 and recirculates 70 percent through a HEPA H14 supply — appropriate for non-volatile cell culture work. A Class II Type B2 BSC vents 100 percent to outdoor and is required for volatile chemical work; B2 is rare in CGT facilities but used in some viral vector work where solvents are involved.

HVAC integration: the BSC exhaust ducts to outdoor through a Type 316L stainless steel exhaust path with HEPA H14 in-line filtration upstream of a dedicated exhaust fan. The cleanroom HVAC supplies the BSC make-up through HEPA H14 ceiling diffusers; the cleanroom returns to the air handler through HEPA H13 return grilles. The BSC and the cleanroom are mutually-balanced — the BSC exhaust draws from the room and the room make-up must compensate.

Viral vector production

Viral vector production (lentiviral, adeno-associated virus AAV, adenoviral) for gene therapy and CAR-T transduction operates under BSL-2 enhanced (containment between BSL-2 and BSL-3 depending on the specific vector and the risk assessment). The vector production suite has a tighter pressure cascade than general cell culture, typically negative 5 to 10 Pa to corridor, with all exhaust HEPA H14 filtered. The vector inactivation step (typically downstream of harvest, before the vector is removed from the cell-culture supernatant) is performed in a closed-system before any open processing occurs.

API synthesis — the chemical manufacturing scope

Active Pharmaceutical Ingredient (API) synthesis is upstream of every pharmaceutical formulation — the synthesis chemistry that produces the active molecule from raw chemical precursors. ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) governs the GMP framework. The HVAC pattern is distinct from finished-dose manufacturing because the room is dominated by chemical hazard rather than cleanroom requirements, the equipment is reactors and process vessels rather than fill lines, and the building is engineered around solvent inventory and hazardous-area classification.

Reactor hall classification

The reactor hall is typically Grade D classified for cleanroom purposes (or unclassified if the product is a non-sterile API for downstream formulation) and AS/NZS 60079 hazardous area classified for chemical safety purposes. Zone 1 (intermittent flammable atmosphere) around the reactor charge points and the solvent transfer manifolds. Zone 2 (rare or short-duration flammable atmosphere) across the broader reactor hall. The classification dossier under AS/NZS 60079.10.1 sets out the precise extent of each zone, the equipment selection requirements, and the ventilation rate sufficient to maintain the classification.

Solvent inventory and dilution ventilation

API synthesis handles solvent inventory at the kilogram-to-tonne scale. Ethanol, isopropanol, methanol, acetone, methyl ethyl ketone (MEK), tetrahydrofuran (THF), dichloromethane, ethyl acetate, toluene, hexane and water are common solvents. Each has a Safe Work Australia WES (ethanol 1,000 ppm 8-hour TWA, isopropanol 400 ppm, methanol 200 ppm, acetone 500 ppm, MEK 200 ppm, hexane 50 ppm) and a lower flammable limit that drives the dilution ventilation calculation. The reactor hall is sized for the peak credible release event (often a charge-point spill or a reactor seal failure) holding the room airborne concentration below 25 percent of the LFL of the controlling solvent.

Process exhaust segregation

Solvent vapour exhaust segregation by chemistry is mandatory. Ethanol, isopropanol and methanol may share an exhaust path. Acetone and MEK share a path. Halogenated solvents (dichloromethane, chloroform where still used) require a dedicated path because thermal oxidation produces hydrogen chloride that demands acid-resistant downstream equipment. Acid-evolving reactions (sulfuric acid, hydrochloric acid, acetic anhydride, oxalyl chloride) exhaust through an acid scrubber before reaching any common exhaust system. Cyanide-evolving reactions (rare in modern API but still present in some legacy chemistries) require dedicated cyanide-specific exhaust treatment.

Regenerative thermal oxidiser (RTO)

Solvent vapour exhaust from API synthesis is rarely discharged untreated. The standard treatment is a regenerative thermal oxidiser (RTO) that combusts the solvent vapour at 800 to 1,000 degrees Celsius, producing carbon dioxide and water vapour, with thermal regeneration of the ceramic beds providing greater than 95 percent thermal efficiency. RTO output meets Victorian EPA, NSW EPA and equivalent state environmental approval conditions for volatile organic compound (VOC) discharge. Some facilities operate solvent recovery condensers (refrigerated or chilled-water-cooled) upstream of the RTO to capture saleable solvent for reuse, with the residual vapour going through the RTO for compliance.

Explosion relief

The reactor hall and the solvent storage areas are protected by explosion-relief panels sized per NFPA 68 (Standard on Explosion Protection by Deflagration Venting) on the building envelope and on the process exhaust ductwork. Vent area is calculated from the volume, the maximum permitted internal pressure rise, the deflagration index of the controlling solvent vapour, and the vent panel set pressure. A typical reactor hall of 1,000 cubic metres handling solvent vapour requires 15 to 40 square metres of explosion relief area distributed across the exterior wall and roof.

Vaporised hydrogen peroxide (VHP) decontamination

Vaporised hydrogen peroxide (VHP) is the standard biocontamination control method for sterile pharmaceutical cleanrooms in 2026 — replacing formaldehyde fumigation (carcinogenic, slow aeration, expensive disposal) and largely replacing chlorine dioxide gas (effective but corrosive to many materials). VHP is used for isolator decontamination between batches (15 to 30 minute cycle), RABS decontamination between batches, and full-room bio-decontamination of Grade A and Grade B suites between campaigns (60 to 90 minute cycle).

The VHP cycle

A VHP cycle delivers 30 to 35 percent hydrogen peroxide solution vaporised by a VHP generator into the sealed cleanroom. Peak concentration is 1,000 to 2,000 ppm depending on the cycle target and the room volume. Contact time is typically 30 to 90 minutes during which the H2O2 oxidises microbial contamination on every accessible surface. Aeration follows: the HVAC drives the H2O2 down below the Safe Work Australia 1 ppm 8-hour TWA before staff re-entry. The full cycle (sealing, conditioning, decontamination, aeration) takes 4 to 8 hours.

HVAC integration

The cleanroom HVAC must isolate during the VHP contact phase and provide high-flow once-through aeration after. The supply and return ducts at every cleanroom designed for VHP decontamination are fitted with bubble-tight isolation dampers. During VHP: the cleanroom HVAC is isolated and the VHP generator recirculates inside the sealed room through its own dedicated recirculation path. During aeration: the cleanroom HVAC opens at maximum ACH with all return diverted to outdoor (no recirculation) until the H2O2 falls below 1 ppm.

Dedicated H2O2 vapour sensors at multiple points (breathing height inside the cleanroom and at the room return path) feed the BMS with alarm thresholds at 0.5 ppm (early warning) and 1 ppm (Safe Work Australia limit). Re-entry only after a documented sub-1 ppm reading on every sensor sustained for a documented minimum dwell. The aeration phase exhaust discharges to outdoor at the same discharge points used by the BSL-3 and API exhaust paths — minimum 3 metres above roof, minimum 8 metres horizontal from any outdoor air intake, minimum 12 m/s discharge velocity.

Bubble-tight damper specification

The VHP isolation damper is the load-bearing engineering item. Specification: bubble-tight (Class 4 leakage to AMCA 511, less than 5 cubic centimetres per second per square metre at design pressure), Type 316L stainless steel construction, EPDM or silicone seal compatible with H2O2 vapour at 2,000 ppm peak, fail-position defined by the cleanroom's fail-safe logic (typically fail-closed on the supply, fail-open on the return for emergency egress airflow). Position-sensor feedback to the BMS. Annual inspection of seals and leak-test on a documented periodicity.

Stability chamber rooms and walk-in environmental chambers

ICH Q1A (Stability Testing of New Drug Substances and Products) requires stability studies under controlled-environment conditions to establish shelf life and storage labelling. The four standard conditions: 25 degrees Celsius / 60 percent RH (long-term, the climatic zone II reference for temperate markets), 30 degrees Celsius / 65 percent RH (intermediate, climatic zone IVa), 40 degrees Celsius / 75 percent RH (accelerated stability), and 5 degrees Celsius (refrigerated stability for cold-chain products).

At smaller scale, stability is conducted in chamber-scale units (Memmert, Binder, Weiss Technik and equivalents). At the scale of a major Australian pharmaceutical site — CSL Parkville, Moderna Clayton, Catalent Braeside, IDT Boronia — walk-in stability rooms are operated to provide larger sample capacity and bay-style storage. HVAC: dedicated AHU per room with PID control on temperature and humidity, supply through HEPA H13 terminal filtration (to prevent particulate contamination of stability samples), Type 316L stainless steel ductwork because the rooms run continuously at elevated humidity (75 percent RH at the accelerated condition challenges galvanised). BMS logging at 5-minute resolution minimum, retained for the life of the stability study plus 7 years per TGA GMP and ICH Q1A.

Mapping studies under ICH Q1A and WHO TRS 961 verify temperature and humidity uniformity at handover (typically less than 1 degree Celsius and 5 percent RH variation across the working volume) and re-verified annually. The mapping report identifies the worst-case bay for the most-vulnerable sample storage allocation.

Cold-chain and ultra-low temperature storage

Vaccine, biologic, mRNA and cell-therapy storage operates across four temperature bands depending on the product and the stage of the supply chain.

Refrigerated 2 to 8 degrees Celsius

The standard refrigerated band for most vaccines and biologics is 2 to 8 degrees Celsius. Storage is in walk-in cold rooms (typically 50 to 500 cubic metres at a major manufacturer) or large pharmaceutical-grade refrigerators with continuous temperature monitoring. HVAC integration: the cold room is conditioned by its own refrigeration plant (Bitzer, Copeland, Mycom or equivalent compressor with R448A or R449A refrigerant for new builds, R404A or R134a for legacy installations). The room body needs supplementary AHU conditioning for the heat load from access frequency, door cycling and electrical equipment. Backup power and refrigeration redundancy is the dominant design issue. WHO TRS 961 sets the validation framework for cold-chain mapping; ICH Q1A defines the stability and shelf-life relationship.

Frozen minus 20 degrees Celsius

The intermediate frozen band for certain biologics and some vaccine intermediates. Walk-in freezer rooms or chest-style freezers with continuous monitoring. Same HVAC and validation pattern as the 2 to 8 degrees Celsius band, scaled colder.

Ultra-low minus 80 degrees Celsius

Cell banks, working seed banks, mRNA bulk product, certain bulk drug substance and certain vaccine intermediates require minus 80 degrees Celsius (or in some cases minus 70 degrees Celsius). Storage is in ultra-low freezers (typically chest or upright units from Thermo Scientific, Eppendorf, Stirling or Haier) inside a conditioned room. The room body HVAC handles the heat rejection from the freezer compressors (3 to 8 kW per upright unit) and maintains the ambient temperature within the freezer's operating envelope (typically 15 to 30 degrees Celsius ambient). Backup power and freezer-by-freezer alarm monitoring is essential.

Cryogenic minus 150 degrees Celsius

Finished mRNA drug product (in some formulations), certain cell therapies, master cell banks and reference materials are stored at liquid nitrogen vapour phase temperatures around minus 150 degrees Celsius (or in some cases liquid phase at minus 196 degrees Celsius). The storage vessel is a vacuum-insulated Dewar with continuous liquid nitrogen replenishment. HVAC: the cryogenic storage room is conventionally ventilated with ACH sized to manage liquid nitrogen evaporation (one cubic metre of liquid nitrogen evaporates to approximately 700 cubic metres of gaseous nitrogen at standard conditions) and oxygen depletion monitors with BMS alarming at 19.5 percent (Safe Work Australia minimum safe oxygen concentration). Emergency ventilation activates on oxygen alarm.

Radiopharmaceutical cyclotron suites

Radiopharmaceutical production — Telix Pharmaceuticals (ASX:TLX) and its Illucix and Pixclara products, Clarity Pharmaceuticals (ASX:CU6), Cyclotek, the GenesisCare radiopharmacy network and the cyclotron operations at major teaching hospitals (Austin Health, Royal Brisbane and Women's, Peter MacCallum Cancer Centre) — couples a medical cyclotron producing positron-emitting isotopes with a downstream GMP radiochemistry hot cell line.

The cyclotron vault

The cyclotron itself is a heavily-shielded particle accelerator (typically 11 to 18 MeV proton energy for medical isotope production) that produces F-18, Cu-64, Ga-68, Zr-89 and other isotopes by proton bombardment of stable target materials. The vault is shielded with 1.5 to 2.5 metres of reinforced concrete plus borated polyethylene for neutron shielding. HVAC: dedicated low-rate ventilation (typically 4 to 6 ACH) with the supply and exhaust passing through labyrinthine penetrations in the shielding to prevent radiation leakage paths. The exhaust passes through HEPA H14 and is monitored for radioactive aerosols before discharge.

The radiochemistry hot cell line

The hot cell line is where the produced isotope is converted into a radiopharmaceutical — chelator conjugation, peptide labelling, purification by HPLC, sterile filtration and final formulation. Each step occurs inside a lead-shielded hot cell (typically 60 to 100 millimetres of lead shielding on the walls and viewing window). The hot cells sit inside a Grade C cleanroom envelope; the cleanroom HVAC provides the operator environment and the hot cell interior has its own dedicated ventilation.

Hot cell exhaust passes through HEPA H14 and an activated carbon bed for volatile radioiodine and radio-gas capture, then through a delay tank that allows short-lived isotopes to decay before discharge to atmosphere. Discharge is monitored continuously by radiation detectors with alarm thresholds tied to the Radiation Safety Plan and ARPANSA regulations. BMS integration with radiation monitoring overlay — exhaust HEPA filter change-out is a radiation-exposure event managed under separate Radiation Safety Plan and not simply a maintenance event.

Quality control microbiology laboratory and environmental monitoring

Every GMP pharmaceutical manufacturing facility operates an in-house Quality Control microbiology laboratory for environmental monitoring (active and passive air sampling, surface contact plates, settle plates), water testing, product bioburden testing, sterility testing and microbial identification. The laboratory operates under BSL-2 (or BSL-3 for vaccine seed work) with Class II A2 biosafety cabinets for open work.

HVAC: BSL-2 laboratory at slightly negative pressure to the corridor (typically minus 5 Pa), HEPA H13 supply, BSC exhaust to outdoor through HEPA H14, Type 316L or 304 stainless steel ductwork depending on chemistry exposure. The sterility testing area sits within a Grade B isolator or RABS (the same engineering pattern as manufacturing aseptic processing) because false positives on sterility testing trigger costly batch rejections and re-testing. Environmental monitoring data feeds the QC LIMS (laboratory information management system) and is reviewed against the Contamination Control Strategy alert and action limits.

Hospital pharmacy compounding under USP <797> and USP <800>

Hospital pharmacy compounding of sterile preparations — chemotherapy reconstitution, total parenteral nutrition, custom sterile injectables, ophthalmic preparations — operates under USP <797> (sterile compounding) and USP <800> (hazardous drug handling). The HVAC pattern is a smaller-scale subset of pharmaceutical manufacturing aseptic processing.

Compounding occurs inside a Primary Engineering Control (PEC) — typically a Class II Type A2 biological safety cabinet for USP <800> hazardous drugs, or a laminar airflow workbench (LAFW) for USP <797> non-hazardous sterile compounding. The PEC sits inside a Secondary Engineering Control (SEC) — a buffer room at ISO Class 7 with HEPA H14 supply, sized for the compounding workload. The buffer room is adjacent to an ante-room at ISO Class 8 for gowning and material staging. Pressure cascade: buffer room positive to ante-room positive to corridor for USP <797> non-hazardous; buffer room negative to ante-room positive to corridor for USP <800> hazardous drug compounding (the negative buffer room contains the hazardous drug aerosol while the positive ante-room prevents corridor air entering).

Hospital pharmacy compounding is operated by major hospital networks (Westmead, Royal Melbourne, Royal Adelaide, Princess Alexandra, Sir Charles Gairdner) and by specialist compounding providers (Slade Pharmacy, various community pharmacy compounding groups). The HVAC scope is smaller than a pharmaceutical manufacturing facility but the engineering principles are the same.

The Australian operator landscape

Australia hosts a concentrated pharmaceutical manufacturing sector across three segments: flagship biopharmaceutical manufacturers operating at global scale, multinational pharmaceutical company Australian operations, and contract manufacturers and specialist biotechs.

CSL Limited and CSL Seqirus

CSL Limited (ASX:CSL) is Australia's flagship biotechnology company — the largest by market capitalisation among ASX-listed manufacturers and one of the world's leading plasma fractionation and biopharmaceutical operators. CSL operates major manufacturing at Parkville VIC (the original Commonwealth Serum Laboratories site, now CSL Behring's plasma fractionation facility) and Broadmeadows VIC (manufacturing of vaccines and other biopharmaceuticals). CSL Seqirus is the influenza vaccine business operating from Parkville — Australia's only on-shore influenza vaccine manufacturer, producing the egg-based and cell-culture-based seasonal influenza vaccines for Australian and export markets. CSL Behring manufactures plasma-derived therapies, recombinant biotherapies and certain vaccines.

Moderna Australia

Moderna Australia operates an mRNA vaccine manufacturing facility at Monash University Clayton VIC, established as part of the Commonwealth Government's domestic mRNA manufacturing capability programme. The facility produces seasonal influenza and pandemic-response mRNA vaccines for Australia and the Asia-Pacific. The facility represents the modern mRNA HVAC design pattern: Grade A isolator fill-finish, Grade B background, Grade C LNP formulation with ATEX classification, Grade C upstream IVT, and the cold-chain and ultra-low-temperature finished-product storage required for mRNA stability.

Multinational pharmaceutical Australian operations

Pfizer Australia operates manufacturing at Bentley WA and legacy operations at Granville NSW. GlaxoSmithKline Australia operates major manufacturing at Boronia VIC and Ermington NSW. Sanofi Australia operates at Lyne NSW and Macquarie Park. AstraZeneca Australia operates at Macquarie Park, North Ryde and Aldridge SA. Bristol-Myers Squibb Australia, Merck Sharp & Dohme MSD Australia (Macquarie Park NSW), Roche Products and Roche Diagnostics (Dee Why and Mascot), Novartis Australia (Macquarie Park), Eli Lilly Australia (West Ryde NSW), Janssen Cilag, Bayer Australia and Boehringer Ingelheim Australia (North Ryde) round out the multinational presence. Most multinational operations focus on packaging, secondary manufacturing and country-specific QC, with primary manufacturing increasingly consolidated at global centres — though several multinational sites in Australia retain primary manufacturing capability for specific products.

Contract manufacturers

IDT Australia (ASX:IDT) at Boronia VIC operates a major contract manufacturing facility producing generics, APIs and specialty pharmaceuticals. Catalent Australia at Braeside VIC operates contract pharmaceutics including sterile fill-finish. Apotex Australia at Macquarie Park and Arrotex Pharmaceuticals operate generic medicines manufacturing. Aspen Pharmacare Australia operates manufacturing capability across multiple sites. Viatris Australia (the former Mylan operation post-merger with Upjohn) operates manufacturing at multiple sites. Astellas Pharma Australia provides specific manufacturing services. Generic Health operates manufacturing in Box Hill VIC — an SBKJ neighbour, illustrating that Australian pharmaceutical manufacturing is concentrated in the same industrial corridors that SBKJ serves with its duct fabrication customer base.

Biotechs, cell therapy and radiopharmaceutical

Australia's biotechnology sector is concentrated in clinical-stage development with a growing manufacturing footprint. ResMed (ASX:RMD) at Bella Vista NSW manufactures CPAP and ventilator devices (medical device rather than pharmaceutical but adjacent in HVAC requirements). Cochlear (ASX:COH) at Macquarie Park manufactures cochlear implants. Mesoblast (ASX:MSB) operates allogeneic mesenchymal stem cell therapy manufacturing. Imugene (ASX:IMU) operates oncolytic virotherapy and cancer vaccine development. Patrys (ASX:PAB), Race Oncology (ASX:RAC) and Cynata Therapeutics (ASX:CYP) operate clinical-stage development. Avita Medical (ASX:AVH) operates Spincyte regenerative skin therapy manufacturing. Telix Pharmaceuticals (ASX:TLX) is Australia's leading theranostic radiopharmaceutical company, producing diagnostic and therapeutic radiopharmaceuticals from cyclotron-coupled GMP suites. Clarity Pharmaceuticals (ASX:CU6) operates radiopharmaceutical development. Genea Biocells operates cell line development.

Vaccine manufacturers (other than CSL Seqirus and Moderna)

Sanofi Pasteur Australia is the Australian operation of the global Sanofi vaccine business, distributing globally-manufactured vaccines into Australian markets. BioCSL was the brand of CSL's pre-Seqirus vaccine operation. The vaccine sector in Australia is heavily concentrated at CSL Seqirus and Moderna; other vaccine manufacturers operate primarily as distribution and clinical-trial supply rather than primary manufacturing.

Industry bodies and regulatory framework

Medicines Australia represents the multinational research-based pharmaceutical industry. The Generic and Biosimilar Medicines Association (GBMA) represents the generic and biosimilar manufacturers. AusBiotech represents the broader biotechnology sector. The Therapeutic Goods Administration (TGA) is the primary regulator under the Department of Health and Aged Care. The Department of Agriculture, Fisheries and Forestry (DAFF) has overlapping responsibility for veterinary medicines and some biological products. State environmental protection authorities (Victorian EPA, NSW EPA, Queensland Department of Environment and Science, SA EPA, WA Department of Water and Environmental Regulation) approve site environmental discharges including HVAC exhaust to atmosphere.

Ductwork material selection — the decision matrix

A fully stainless pharmaceutical GMP HVAC package costs 3 to 6 times a galvanised equivalent and is not always necessary — though more often than in other building types. The cost-effective pattern concentrates Type 316L stainless steel in the GMP-classified cleanroom envelope and chemical and biological exposure zones, uses Type 304 stainless steel in less-critical support zones, and uses galvanised in unclassified support.

Type 316L stainless — mandatory zones: (1) Grade A, B and C supply, return and exhaust ductwork; (2) BSL-3 vaccine manufacturing supply, return and exhaust; (3) lyophiliser room exhaust; (4) vacuum pump exhaust paths; (5) VHP-rated isolation damper sections and downstream aeration exhaust; (6) API synthesis solvent vapour exhaust; (7) acid scrubber exhaust on acid-evolving reactions; (8) radiopharmaceutical hot cell exhaust; (9) cell and gene therapy biosafety cabinet exhaust; (10) cleanroom return paths in any cleanroom designed for VHP decontamination; (11) any duct passing chloramine, peracetic acid, hydrogen peroxide, glutaraldehyde, OPA, ETO, formaldehyde, ethanol, isopropanol, methanol, acetone, MEK, hexane or other solvents at exposure-relevant concentrations.

Type 304 stainless — recommended zones: (1) Grade D supply where vapour exposure is benign; (2) cleanroom return paths in cleanrooms that do not use VHP and have low chemical exposure; (3) stability chamber room supply and return; (4) cold-chain storage room conditioning supply; (5) QC microbiology laboratory supply.

Galvanised (G90 minimum) — acceptable zones: (1) unclassified corridors; (2) warehouse spaces; (3) plant rooms; (4) administrative offices; (5) staff amenities; (6) dispatch and receiving; (7) cyclotron vault ventilation paths inside the shielded vault (the radiation-shielded vault excludes the conventional cleanroom chemistries and the ductwork operates in a benign environment).

Coil traceability and TGA audit. Any stainless duct section installed in an Australian TGA-licensed pharmaceutical manufacturing facility must be mill-certified with the heat number traceable to the finished duct section. TGA GMP, PIC/S PE 009 and EU GMP Annex 1 all expect material provenance to be auditable. SBKJ supplies the SBAL-V configured with coil release tracking that captures the heat number at line entry and ties it to the production batch, satisfying TGA audit and FDA pre-approval inspection without site-fabrication reconciliation.

HEPA filtration strategy and validation

HEPA filtration sits at the heart of every pharmaceutical GMP HVAC specification. Grade A supply uses HEPA H14 (99.995 percent at the most penetrating particle size, MPPS) inside the isolator or RABS canopy. Grade B supply uses HEPA H14 terminal in the room ceiling. Grade C supply uses HEPA H14 or H13 (99.95 percent at MPPS). Grade D supply uses HEPA H13. The validation regime is set by IEST-RP-CC034 (in-place HEPA filter integrity testing) and ISO 29463 (HEPA filter classification).

H13 versus H14

H14 captures 99.995 percent at MPPS — a 10-fold reduction in penetration compared with H13. H14 is the modern standard across Grade A, B and C; H13 is acceptable for Grade D background and for return-air HEPA in cleanrooms that draw from a sufficiently-classified source. Some specialist applications (radiopharmaceutical exhaust, BSL-3 exhaust) move to U15 or U16 (ULPA grade) at 99.9995 percent or better.

Plenum design and gel seal

Every HEPA filter sits in a plenum box with a gel seal frame — a viscous silicone or polyurethane compound in a channel around the filter perimeter into which the filter's knife-edge gasket seats. The gel seal accommodates minor dimensional variation, holds across thermal cycling and VHP exposure, and is straightforward to validate at change-out. The plenum has an upstream test port for PAO challenge injection and a downstream port for photometer scanning.

Plenum fabrication is the demanding test of duct manufacturing capability. A 2 mm out-of-square on the filter seat compromises the gel seal and the filter leaks past the frame. SBKJ supplies the SBAL-V configured to produce plenum sections to dimensional tolerance — the TDF flanging operation accepts gel seal frame integration, and the cutting and bending tolerances are tight enough to meet the seal-class requirements without site-fabrication hand-shimming.

Validation at handover and ongoing

Every terminal HEPA filter is validated per IEST-RP-CC034 — PAO aerosol challenge injected upstream at 10 to 20 micrograms per cubic metre, calibrated photometer scans the filter face and frame seal downstream, acceptance no penetration above 0.01 percent for H14 or 0.05 percent for H13. Re-validation is annual for Grade A and B, every two years for Grade C and D, or more frequent if BMS records show pressure-drop excursions. Filters are replaced at twice clean-state differential with full validation on replacement.

Construction class, joint integrity and seal classes

Pharmaceutical GMP ductwork is fabricated to higher construction standards than most other building HVAC. The combination of pressure class, leakage class and seal class drives the fabrication detail.

AS 4254 pressure class

Most pharmaceutical cleanroom supply ductwork falls into AS 4254 Class B (medium pressure, up to 750 Pa positive). BSL-3 exhaust, API solvent exhaust, lyophiliser vacuum exhaust, radiopharmaceutical hot cell exhaust and any duct serving a high-static fan against significant external resistance fall into Class C (high pressure, up to 1,500 Pa). Sheet thickness, joint design, stiffener spacing and support spacing are calibrated to the class per AS 4254 Part 2.

Leakage class

SMACNA Leakage Class 6 or better (3 cfm per 100 sq ft at 1 inch wg, equivalent to 1.5 L/s per square metre at 250 Pa) is the EU GMP Annex 1 expectation for general pressurised cleanroom ductwork. Class 9 or better (functionally airtight) is the BSL-3 expectation. The test pressure is 1.5 times maximum operating pressure. Each duct section is tested before insulation; failure triggers re-fabrication or sealing re-work.

SMACNA Seal Class A equivalent

All pharmaceutical GMP cleanroom ductwork is sealed to SMACNA Seal Class A equivalent — every transverse joint, every longitudinal seam, every duct wall penetration sealed. Sealants are UL 181 listed, low-VOC and compatible with VHP exposure where applicable. For Type 316L stainless steel duct, continuously TIG-welded longitudinal seams replace mechanical sealing on the seam, with gasketed and sealed TDF flanges at every transverse joint. The result is a fully welded, leak-tight, Class A SMACNA seal class duct system throughout the GMP envelope.

Fire and smoke compartmentation

A pharmaceutical manufacturing facility typically comprises multiple fire compartments, with the GMP cleanroom envelope often forming its own fire compartment for isolation from surrounding warehouse, plant and administrative areas. Fire and smoke dampers are required at every smoke partition crossing and at every floor crossing under AS 1668.1 and AS 1530.4. AS 1851 governs the maintenance regime.

For Type 316L stainless steel duct sections, the damper sleeve installation must not compromise the welded-seam integrity. The standard practice is to install the damper sleeve as a separate fabricated unit, joined to the duct sections with gasketed TDF flanges, and the damper assembly tested as a system rather than the duct being cut into post-installation. Damper actuator power and monitoring is tied to the BMS with fault and position logging.

For BSL-3 exhaust ductwork, fire damper integration requires careful coordination because the duct must maintain containment integrity through any credible fire event — the damper's biocontainment function and its fire function must be satisfied simultaneously. Specialised combination fire/smoke/biocontainment dampers (rare in conventional construction) are used for the limited number of BSL-3 fire-compartment crossings.

BMS integration under EU GMP Annex 11

The pharmaceutical GMP BMS is a GxP-validated computerised system under EU GMP Annex 11 (and US FDA 21 CFR Part 11 where the facility exports). The BMS validation discipline (DQ/IQ/OQ/PQ) is the same as for any other GxP system — the difference is that the data being monitored is HVAC operating data rather than process data, and the consequences of data loss or data integrity failure are equally severe.

Pressure transducers. Permanent differential pressure transducers at every cascade boundary: every Grade A to Grade B transition (isolator and RABS), every Grade B to Grade C, every Grade C to Grade D, every Grade D to unclassified, BSL-3 to corridor, every airlock chain step. Logging at 1-minute resolution minimum, more often through transient events. Warning at 50 percent of design differential, critical alarm at 25 percent or inversion.

Temperature and humidity loggers at every Grade A/B/C/D zone, stability room, cold-chain storage, ultra-low freezer room and cryogenic storage. Resolution 5-minute minimum (1-minute for critical zones). Data retained for the life of the manufactured batch plus 5 years minimum per TGA GMP, longer per FDA where the facility exports.

HEPA differential pressure across every filter bank, with a change-out alarm at twice the clean-state value. Data used to predict change-out intervals and to optimise the maintenance schedule.

Vapour monitors at breathing height in the relevant zones — hydrogen peroxide near every VHP-capable cleanroom (alarm at 0.5 and 1 ppm), peracetic acid in any peracetic-using area (0.4 ppm STEL), ethanol and the LNP-formulation solvent panel in mRNA suites, hexane, acetone, MEK, methanol and isopropanol in API synthesis halls. Annual calibration with documented certificates. ATEX certification on monitors located in classified zones.

Particle counters for routine ISO 14644 monitoring at the documented periodicity, plus continuous monitoring in Grade A and Grade B per Annex 1 (2022) requirements. Particle data feeds the Contamination Control Strategy review.

Door position sensors and visual indicators. Door position sensors allow the BMS to distinguish door-closed equilibrium pressure from door-open transient. Cascade verified at door-closed; door-open transients logged but not alarmed unless they exceed the documented recovery time (typically 30 to 60 seconds). Green/red LED indicators at every door let staff confirm cascade direction without consulting the BMS screen.

Audit trail and data integrity. Annex 11 requires audit-trail capability on every change to a GxP record. Access control with named users, no shared accounts, password complexity per the validated policy. Backup and disaster recovery to a documented Recovery Time Objective. Annual periodic review of audit-trail data is a GMP expectation.

Construction sequencing and the SBKJ machine pattern

A new-build pharmaceutical GMP HVAC scope typically runs 9 to 18 months from possession through commissioning, longer for major aseptic fill-finish or BSL-3 work. The sequence is broadly: months 1 to 3 demolition (in retrofit), base-build alterations and structural penetrations; months 2 to 5 fabrication and delivery of the 316L stainless steel exhaust hoods, isolator make-up plenums, HEPA terminal plenums and BSL-3 BIBO filter housings; months 4 to 9 ceiling-void rough-in for supply, return, exhaust, BMS and process services; months 7 to 12 partition installation, ceiling closure, HEPA plenum mounting and isolator installation; months 10 to 14 diffuser, grille, HEPA filter installation and process equipment integration; months 12 to 16 SMACNA leakage testing, pressure verification and ISO 14644 validation; months 14 to 18 final commissioning, BMS DQ/IQ/OQ/PQ validation, VHP cycle qualification, contamination control strategy verification, and TGA licence application or pre-approval inspection.

The SBKJ machine recommendation

The SBAL-V auto duct line is the SBKJ flagship for the high-output, stainless-capable fabrication required by pharmaceutical GMP scopes. Specifications: 16 metres per minute working speed, 87 kilowatt installed power, 0.5 to 1.5 millimetre coil thickness, 1,500 millimetre maximum coil width. The line is configured for Type 316L stainless coil with mill-certified traceability — the coil release record captures the heat number at line entry and ties it to the production batch, satisfying TGA GMP, PIC/S PE 009 and EU GMP Annex 1 audit expectations. The TDF flanging operation accepts gasketed sealing for HEPA-grade integrity and for VHP-rated bubble-tight damper integration. The line handles galvanised, Type 304 and Type 316L coil through the same forming train with a documented changeover sequence, so a single shift can fabricate multiple material specifications for the same pharmaceutical project. Fully welded leak-tight Class A SMACNA seal class throughout the GMP envelope is non-negotiable; the SBAL-V production pattern delivers it as a routine output rather than as a premium add-on.

For fabricators serving pharmaceutical projects as part of broader healthcare and cleanroom packages, the SBAL-III (14 metres per minute, 15.7 kilowatt) is the cost-effective workhorse. The SBAL-II (18 metres per minute, 5.5 kilowatt) suits smaller specialist GMP and contract-manufacturing fit-outs where throughput requirements are lighter. The SBTF-1500C, SBTF-1602 and SBTF-2020 TDF flange formers produce the gasketed transverse joints; the SBEM-1250 elbow former handles the changes of direction through ceiling voids.

For round duct serving cleanroom return risers, HEPA bank distribution, lyophiliser exhausts and VHP aeration paths, the SBSF-1525 spiral former (2.5 kilowatt) handles the bulk of the work. The larger SBFB-1500 (7.5 kilowatt, 1.20 metres per minute) handles higher-pressure spiral where AS 4254 Class C and SMACNA Class 9 leakage requirements drive the construction class up. The SBHF hydraulic folder and the SBPC1500 plasma cutter handle the bespoke transitions, offsets and HEPA plenum cutouts that no automatic line can match.

Welded stainless components — isolator make-up plenums, BSL-3 BIBO filter housings, lyophiliser exhausts, radiopharmaceutical hot cell exhausts, API solvent vapour exhausts and acid scrubber housings — are produced using SBKJ stitchwelder equipment, including the SBSF-1525 stitchwelder, with full TIG seam welding for pressure-vessel-grade integrity. The SBLR-600 and SBLR-600A longitudinal welders (7.6 metres per minute) handle the long stainless seams characteristic of GMP exhaust hood and isolator make-up plenum fabrication.

Joint integrity for HEPA-filtered and VHP-compatible systems

Duct joints in HEPA-filtered supply and VHP-compatible systems require integrity beyond conventional ducted HVAC: gasketed and sealed TDF flanges with VHP-compatible EPDM or silicone gaskets, mastic or butyl sealant on every joint, fully torqued clamps. The SBKJ TDF auto-cleating and flanging operation produces joint geometry that accepts this sealing without site-fabrication rework — the gasket seats cleanly, the sealant beads adhere, and the clamp torque is repeatable across the install. Internal acoustic lining is generally prohibited in pharmaceutical GMP cleanroom ductwork (sheds fibres that compromise HEPA loading and contaminate the filtered air stream); external acoustic wrap with foil facing and low-VOC binder is the standard.

Commissioning, validation and operational handover — DQ/IQ/OQ/PQ

A pharmaceutical GMP HVAC system is not commissioned until every key parameter has been measured, recorded and signed off through the DQ/IQ/OQ/PQ framework. The handover binder is the basis of every TGA inspection, every PIC/S audit and every FDA pre-approval inspection through the facility lifetime.

Design Qualification (DQ)

The DQ documents that the HVAC design meets the user requirements (URS) and the regulatory requirements (TGA, PIC/S, EU GMP Annex 1, ICH where applicable). DQ deliverables: URS sign-off; Functional Specification (FS); Design Specification (DS); HAZOP and risk assessment under ICH Q9; review of compliance with EU GMP Annex 1 (2022) for sterile manufacturing scope. DQ is completed before fabrication.

Installation Qualification (IQ)

IQ documents that the HVAC system is installed in accordance with the design and the manufacturer's specification. IQ deliverables: as-installed drawings; equipment serial number register; material certificates for every stainless coil heat number; SMACNA leakage test reports per section; calibration certificates for every BMS sensor and transducer; piping and instrumentation diagram (P&ID) sign-off; pre-commissioning checklist sign-off. IQ is completed before start-up.

Operational Qualification (OQ)

OQ documents that the HVAC system operates within design parameters across the full operating range. OQ deliverables: air balancing report (every diffuser, grille and exhaust measured); pressure relationship verification per cascade boundary; ACH verification per zone; temperature and humidity baseline over 7 days minimum; HEPA integrity test per filter per IEST-RP-CC034; ISO 14644 particle count validation per zone; vapour monitor calibration; BMS point list verification; alarm threshold verification by simulated faults; fire and smoke damper test per damper; VHP cycle test where applicable; emergency power changeover test for BSL-3 and other critical-power zones. OQ is completed before product introduction.

Performance Qualification (PQ)

PQ documents that the HVAC system operates within design parameters under routine production conditions. PQ deliverables: ISO 14644 in-operation particle count per zone; environmental monitoring with settle plates, surface contact plates and active air sampling over the documented qualification period; contamination control strategy validation; media fill simulation for aseptic operations; smoke pattern testing for unidirectional flow zones (Grade A); recovery time testing after simulated upset; full BMS data review for the qualification period. PQ is completed before commercial production release.

The handover binder

The handover binder integrates the DQ/IQ/OQ/PQ outputs with: SMACNA/AS 4254 leakage test reports per duct section; pressure relationship test logs; ACH verification logs per diffuser and grille; HEPA integrity certificates per filter; ISO 14644 particle count validation per zone; temperature and humidity baseline and 7-day routine logs; BMS point list with alarm verification; vapour monitor calibration certificates; mill certificates per stainless heat number with traceability to the duct section; AS/NZS 60079 hazardous area classification dossier where applicable; BSL-3 containment certificate where applicable; VHP cycle qualification report where applicable; ATEX certification per item where applicable; radiation safety plan where applicable. The binder is the basis of the TGA licence application and every subsequent inspection through the facility lifetime.

Common pharmaceutical GMP HVAC mistakes — and how to avoid them

The mistakes set out below account for most of the rework we have seen on Australian pharmaceutical GMP HVAC projects. Each is cheap to fix at design stage and expensive (or impossible) to fix on a licensed manufacturing site.

Mistake 1 — Galvanised duct in any Grade A/B/C zone

Galvanised steel sheds zinc oxide particulate under thermal cycling and contaminates the HEPA-filtered air stream. Galvanised is unacceptable in Grade A, B or C supply, return or exhaust under any circumstance. The fix is Type 316L stainless steel across the entire Grade A/B/C envelope, Type 304 acceptable in Grade D where exposure is benign.

Mistake 2 — Wrong stainless grade in chloride-bearing zones

Type 304 stainless lacks the molybdenum content that confers resistance to chloride pitting. Under sustained chloramine, peracetic acid or chloride-bearing cleaning chemistry exposure, Type 304 develops pitting and intergranular corrosion. The fix is Type 316L specifically in chloride-bearing zones, with Type 304 reserved for moderate-exposure supply paths.

Mistake 3 — Missing bubble-tight isolation dampers on VHP-capable rooms

A VHP cycle pushes 1,000 to 2,000 ppm H2O2 vapour through a sealed cleanroom. Without bubble-tight isolation dampers on the supply and return ducts, the H2O2 escapes into the broader HVAC system, contaminating adjacent zones and creating staff exposure issues. The fix is bubble-tight Class 4 leakage dampers on every supply and return at every VHP-capable cleanroom.

Mistake 4 — Recirculation in a BSL-3 vaccine suite

BSL-3 manufacturing demands single-pass once-through ventilation. Any recirculation, even partial, is a containment design failure. The fix is dedicated single-pass HVAC on the entire BSL-3 envelope with no recirculation path under any operational scenario.

Mistake 5 — Inadequate explosion relief on API solvent exhaust

Solvent vapour exhaust ducts that lack explosion-relief paths sized per NFPA 68 are deflagration risks. The fix is explosion-relief panels at sized vent area on the reactor exhaust ductwork, calculated for the volume, the deflagration index of the controlling solvent, and the maximum permitted internal pressure rise.

Mistake 6 — ATEX zone classification missing or wrong

API synthesis halls, mRNA LNP formulation suites and solvent storage rooms with incorrect or missing AS/NZS 60079 zone classification dossiers are ignition incidents waiting to happen. The fix is a formal zone classification per AS/NZS 60079.10.1, ATEX-rated equipment throughout the classified zone, and intrinsically-safe BMS sensors in the zone.

Mistake 7 — HEPA plenum dimensional out-of-square

A 2 mm out-of-square on the filter seat compromises the gel seal and the filter leaks past the frame. The fix is precision fabrication on the SBAL-V line with dimensional control on the cutting and bending operations — rather than site-fabrication that depends on hand-shimming for fit.

Mistake 8 — No condensate management on lyophiliser CIP/SIP exhaust

Steam exhaust ductwork from lyophiliser SIP cycles condenses on every cycle. Without slope back to a trapped drain, condensate collects in low points, corrodes the duct floor and eventually perforates the duct. The fix is 1:50 minimum slope back to a trapped condensate drain on every steam-bearing exhaust duct.

Mistake 9 — Internal acoustic lining in cleanroom ductwork

Internal acoustic lining sheds fibres that compromise HEPA loading and contaminate the filtered air stream. The fix is external acoustic wrap with foil facing and low-VOC binder; internal lining is not appropriate for pharmaceutical GMP work.

Mistake 10 — Combined solvent exhausts without compatibility analysis

Combining solvent vapours from different chemistries into a common exhaust without compatibility analysis is a chemical-hazard risk. Acid-evolving and base-evolving streams must be segregated. Halogenated solvents produce hydrogen chloride at the RTO and require acid-resistant downstream equipment. The fix is exhaust segregation by chemistry, with combined paths only where the chemistry has been verified.

Mistake 11 — Discharge re-entrainment

Decontamination exhaust, solvent exhaust, BSL-3 exhaust and radiopharmaceutical exhaust discharged too close to outdoor air intakes re-enter through the intake. The fix is discharge vertically upward, minimum 3 metres above roof, minimum 8 metres horizontal from any intake, with discharge velocity 12 m/s minimum.

Mistake 12 — BMS not validated under Annex 11

A BMS that is not validated under EU GMP Annex 11 is a GxP non-conformance, regardless of how technically functional the system is. The fix is full DQ/IQ/OQ/PQ validation of the BMS at commissioning, with audit trail, access control, and disaster recovery documented and tested.

Mistake 13 — Missing coil traceability

Stainless duct without mill-certified heat number traceability fails TGA audit and FDA pre-approval inspection. The fix is coil release tracking at fabrication, with the heat number stamped onto each duct section and the mill certificate retained against the heat number in the facility file.

Mistake 14 — No N+1 redundancy on BSL-3 or critical-process exhaust

A single-fan exhaust on a BSL-3 suite or a critical-process exhaust is a single point of failure. Loss of the fan means loss of negative pressure (BSL-3) or loss of containment (chemical exhaust). The fix is N+1 fan redundancy with automatic changeover, monitored on the BMS, and emergency power that holds the exhaust running through grid loss.

Mistake 15 — Annex 1 (2022) gaps in older designs

Pharmaceutical designs developed before the August 2023 effective date of Annex 1 (2022) may not meet the current standard, particularly around the Contamination Control Strategy, isolator/RABS preference, PUPSIT for sterilising filters, and continuous Grade A/B particle monitoring. The fix is design review against the current Annex 1 at every facility update and at every five-year periodic review.

Energy, sustainability and operating cost

A pharmaceutical GMP HVAC system runs continuously — 168 hours per week, 52 weeks per year — because the cleanroom envelope, the pressure cascade and the cold-chain storage must hold continuously regardless of production schedule. The energy cost is significant. For a mid-size pharmaceutical site (CSL Broadmeadows scale, Moderna Clayton scale, a major contract manufacturer at IDT or Catalent scale), HVAC energy is typically 8 to 25 gigawatt-hours per year, equivalent to 1,500 to 5,000 tonnes of carbon emissions at typical Australian grid intensity. Several design choices have the largest effect on operating cost.

First, variable-speed fans on every supply and exhaust. Production demand varies through the day; constant-speed fans waste fan power. Variable-speed drives on every fan, with the BMS modulating speed to maintain pressure cascade and ACH, cuts fan energy by 30 to 50 percent. Second, occupancy-modulated ACH in non-aseptic zones. Grade C and Grade D zones do not need 40 ACH overnight when nobody is in the room; reducing to a maintenance ACH of 6 to 10 overnight while preserving the pressure cascade saves substantial fan and chiller energy. Annex 1 explicitly permits this approach for non-Grade A/B zones. Third, heat recovery on outdoor air paths. Pharmaceutical sites take substantial outdoor air through the AHUs; runaround glycol coils, plate heat exchangers (not thermal wheels because cross-contamination risk is unacceptable), and high-efficiency reverse-cycle heat pumps recover 30 to 50 percent of the conditioning energy.

NCC Section J sets minimum energy efficiency expectations for new and refurbished pharmaceutical fit-outs in Australia, applying to GMP scopes the same as other commercial work though with allowance for the regulatory floor on ACH. Compliance typically requires variable-speed AHU fans, efficient chillers, heat recovery on outdoor air paths, and demand-control where appropriate. A NABERS rating on the host building further constrains the GMP tenancy's HVAC choices.

Refurbishment versus new fit-out

A growing share of Australian pharmaceutical GMP HVAC work is refurbishment of existing facilities to current EU GMP Annex 1 (2022) standards. The refurbishment challenge is fitting modern Annex 1 ACH, HEPA H14 terminal, isolator integration, VHP capability and BMS validation into ceiling voids and AHU plant designed for an earlier specification.

Three common refurbishment patterns: (1) Phased zone-by-zone refurbishment — refurbish one Grade A/B suite first while the rest of the facility continues operating, then progress through Grade C and Grade D over a 12 to 24 month programme. (2) Decant to temporary capacity — set up temporary modular GMP capacity in nearby space or contract a contract manufacturer for the duration of the refurbishment, then refurbish the permanent facility in one continuous programme. (3) Greenfield replacement — build a new GMP block on the same campus or at a new site, transfer manufacturing to the new block, and decommission the legacy block. The third pattern is the strategic choice for major sites where the legacy facility cannot be brought to Annex 1 (2022) without effectively rebuilding it — some CSL, Moderna and contract-manufacturing decisions in Australia have gone this way over the past five years.

Procurement and commercial pattern

Pharmaceutical HVAC procurement runs through three distinct channels in Australia. The multinational pharmaceutical company channel is procured through corporate engineering and capital works teams at Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, MSD, Roche, Novartis, Eli Lilly, Janssen Cilag and Boehringer Ingelheim. Procurement typically runs through a centralised process with country-specific execution; large projects are tendered to specialist GMP construction managers (CPB Contractors GMP work, John Holland Health, Multiplex Health, Lendlease Pharma divisions) who in turn subcontract the mechanical scope to a head contractor who subcontracts ductwork fabrication.

The Australian biopharmaceutical channel — CSL Limited, Moderna Australia, Telix Pharmaceuticals, Mesoblast and the broader ASX-listed biotech sector — procures through internal capital works teams supported by specialist consulting engineers (Aurecon, GHD, AECOM, WSP, Stantec Pharma divisions). Major projects (CSL Behring expansions at Parkville and Broadmeadows, Moderna Clayton, Telix radiopharmaceutical scale-up) run as design-and-construct or managing-contractor packages.

The contract manufacturer channel — IDT Australia, Catalent, Apotex, Arrotex, Aspen, Astellas, Viatris — procures through site capital works programmes that typically run smaller scopes more frequently than the major biopharmaceutical channel. Procurement is often centralised at the corporate level for multi-site rollouts.

SBKJ's role across all three channels is upstream of the project. We supply auto duct production lines — the SBAL-V flagship in 316L specification, the SBAL-III workhorse, the SBAL-II compact — to the mechanical contractors and fabricators producing the ductwork for pharmaceutical GMP scopes nationally. The standard pharmaceutical configuration is the SBAL-V running Type 316L stainless coil for the GMP cleanroom envelope, switching to Type 304 for support zones and to galvanised for the unclassified corridor and warehouse scope, all within a single shift with a documented changeover sequence. The TDF flanging operation runs the same on all three coil types, accepts mastic and butyl sealant for HEPA-grade and VHP-rated integrity, and handles HEPA plenum and isolator make-up plenum fabrication to dimensional tolerance. SBKJ engineers in our Box Hill North Victoria office provide design and fabrication support throughout the project lifecycle with a 12-hour reply commitment to spec questions — from a senior engineer, not a salesperson.

Conclusion — the thirty-year decision

An Australian pharmaceutical GMP manufacturing facility is a 25-to-40-year decision. The HVAC ductwork installed today will still be moving air, holding Grade A/B/C/D pressure cascade, supporting aseptic fill-finish and protecting product quality when the current production team has long retired. Designing it against TGA GMP, PIC/S PE 009 and EU GMP Annex 1 (2022) expectations — Type 316L stainless steel across the GMP envelope, HEPA H14 terminal at Grade A/B/C, continuous BMS monitoring of pressure cascade, temperature, humidity, particle count and vapour, bubble-tight isolation dampers for VHP, fully welded leak-tight Class A SMACNA seal class throughout, robust DQ/IQ/OQ/PQ commissioning and annual re-validation — costs more than a generic ducted HVAC scope. It pays for itself many times over the facility lifetime in reduced contamination risk, sustained compliance through every TGA inspection cycle, lower lifecycle replacement cost (because the corrosion-vulnerable materials are placed correctly at first install), the ability to manufacture for export to US, EU and other PIC/S markets, and continuous product availability to patients in Australia and overseas.

The Australian pharmaceutical and biotech sector is consolidating around the CSL flagship at Parkville and Broadmeadows, the new mRNA capability at Moderna Clayton, the contract manufacturing base at IDT Boronia and Catalent Braeside, the multinational secondary manufacturing footprint at Macquarie Park and across the eastern seaboard, and the emerging radiopharmaceutical and cell-therapy sector led by Telix, Mesoblast, Clarity and Cynata. SBKJ supplies the auto duct production lines that fabricate the ductwork for these facilities — with the SBAL-V as the flagship configured for Type 316L stainless work, the SBAL-III as the workhorse, the SBSF-1525 stitchwelder for HEPA filter housings and isolator make-up plenums, the SBFB-1500 spiral former for higher-pressure spiral return risers, and the broader SBKJ machine pattern (Bending Machine, Stitchwelder, Gorelocker, TDF flanging, spiral forming, plasma cutting) for the bespoke and welded fabrication. Our engineering team in Box Hill North Victoria is available to support fit-out contractors, mechanical consultants and pharmaceutical capital works teams throughout the design and fabrication cycle.

Whether your project is a new-build aseptic fill-finish suite at CSL or a contract manufacturer; an mRNA buildout at Moderna or an emerging Australian mRNA contractor; a BSL-3 vaccine manufacturing scope; a cell and gene therapy cleanroom at Mesoblast, Cynata, Imugene or Avita; an API synthesis hall under ICH Q7 at IDT or a generics manufacturer; a radiopharmaceutical cyclotron suite at Telix, Clarity or a hospital-based PET cyclotron; a hospital pharmacy compounding fit-out under USP <797> and USP <800>; or a refurbishment of an existing facility to current EU GMP Annex 1 (2022) standards — the engineering principles are the same, TGA GMP and PIC/S PE 009 are non-negotiable, EU GMP Annex 1 (2022) is the modern sterile-manufacturing reference, and the design pattern set out in this guide is the SBKJ engineering team's recommended starting point.

Get an SBKJ engineering review of your pharmaceutical GMP HVAC specification →

FAQ

What is the EU GMP Annex 1 (2022) pressure cascade for an Australian aseptic fill-finish facility?

EU GMP Annex 1 (revised 2022, fully effective 2023) and PIC/S Guide to GMP PE 009 require a documented and continuously monitored pressure cascade across Grade A, B, C and D classified zones. Grade A (ISO 14644 Class 5, the aseptic fill-finish critical zone inside an isolator or RABS) sits at +15 Pa to Grade B background. Grade B (ISO Class 7 in operation, the sterile gowning and aseptic background) sits at +10 Pa to Grade C. Grade C (ISO Class 8 in operation) at +5 Pa to Grade D. Grade D at ambient or slightly positive to the unclassified corridor. Every differential is monitored by a permanent transducer logged on the GxP-compliant BMS per EU GMP Annex 11 with door-side visual indicators.

What ductwork material is required for a GMP pharmaceutical cleanroom?

Type 316L stainless steel ductwork is the SBKJ specification standard for Grade A, B and C zones of Australian aseptic fill-finish, biologics, vaccine, mRNA or sterile injectable manufacturing. Galvanised steel is unacceptable in any Grade A/B/C return or supply path because the zinc oxide surface sheds particulate and contaminates the air stream. Type 304 stainless is acceptable in Grade D and unclassified background zones where exposure is benign. Type 316L is the long-life choice for chloride-bearing chemistries and solvent zones. Continuously TIG-welded longitudinal seams, fully passivated, sized to AS 4254 Class C with SMACNA Seal Class A throughout. SBKJ supplies SBAL-V auto duct lines in 316L specification with mill-certified coil traceability.

What air change rate and supply pattern is required for Grade A aseptic fill-finish?

Grade A is defined by unidirectional airflow at 0.36 to 0.54 m/s at the working position. EU GMP Annex 1 (2022) confirms 0.36 to 0.54 m/s as the design target. The Grade A critical zone is enclosed inside a restricted access barrier system (RABS) or an isolator. Grade B background runs 40 to 60 ACH with HEPA H14 supply. Grade C runs 20 to 40 ACH, Grade D runs 10 to 20 ACH. All cleanroom supply is HEPA H14 (99.995 percent at MPPS) or H13 (99.95 percent) for Grade D background.

What HVAC ventilation is required for BSL-3 vaccine manufacturing?

A BSL-3 vaccine manufacturing suite operates under AS/NZS 2243.3 and the WHO Laboratory Biosafety Manual. The suite is held at -25 Pa minimum to the corridor, single-pass once-through ventilation (no recirculation), all exhaust HEPA H14 through gas-tight bag-in bag-out filter housings, autoclave kill-step on all solid and liquid waste, entry/exit airlock chain. Exhaust ductwork is Type 316L stainless steel continuously TIG-welded with full leak-tightness verification. Exhaust fan on N+1 emergency power. Loss of negative pressure for more than 30 seconds is a containment failure event.

What HVAC scope serves an mRNA vaccine manufacturing facility?

mRNA manufacturing splits into three HVAC zones: upstream in-vitro transcription at Grade C/D; lipid nanoparticle (LNP) formulation at Grade C with Zone 2 ATEX classification for ethanol handling; downstream aseptic fill-finish at Grade A inside isolator with Grade B background. The LNP formulation suite is the design-critical area — ATEX-rated equipment, dilution ventilation below 25 percent of the LFL for ethanol, dedicated solvent vapour exhaust to recovery condenser or RTO, intrinsically-safe BMS instrumentation. Finished product holds at -80 to -150 degrees Celsius.

What HVAC ductwork is required for an Active Pharmaceutical Ingredient (API) synthesis suite?

API synthesis is governed by ICH Q7. The synthesis suite is typically Grade D classified with the reactor hall classified as AS/NZS 60079 Zone 1 around reactor charge points and Zone 2 in the broader hall. Type 316L stainless steel continuously TIG-welded with SMACNA Seal Class A integrity. Solvent vapour exhaust through acid scrubber (acid-evolving reactions) and regenerative thermal oxidiser (RTO) before discharge. Explosion-relief panels per NFPA 68. ATEX-rated fans, dampers and instrumentation throughout.

How is vaporised hydrogen peroxide (VHP) decontamination integrated with HVAC?

VHP introduces 30 to 35 percent H2O2 vapour at 1,000 to 2,000 ppm peak for 30 to 90 minute contact time. The cleanroom HVAC isolates during the contact phase by bubble-tight Class 4 leakage isolation dampers on supply and return. During aeration: HVAC at maximum ACH with all return diverted to outdoor (no recirculation) until H2O2 falls below the Safe Work Australia 1 ppm 8-hour TWA. Dedicated H2O2 vapour sensors with BMS alarming at 0.5 and 1 ppm. Re-entry only after documented sub-1 ppm reading.

Which SBKJ machine produces ductwork for pharmaceutical GMP specifications?

The SBAL-V auto duct line is the SBKJ flagship for stainless-capable rectangular duct fabrication serving pharmaceutical GMP scopes — 16 m/min, 87 kW, 0.5 to 1.5 mm coil, 1,500 mm coil width, configurable for Type 316L stainless with mill-certified traceability. For lower-throughput work, the SBAL-III (14 m/min, 15.7 kW) and SBAL-II (18 m/min, 5.5 kW) are alternatives. Round duct uses the SBSF-1525 (2.5 kW) spiral former or the SBFB-1500 (7.5 kW, 1.20 m/min). HEPA plenums, isolator make-up plenums, BSL-3 BIBO housings and lyophiliser exhausts use SBKJ stitchwelder equipment with the SBLR-600/600A longitudinal welders. Fully welded leak-tight Class A SMACNA seal class throughout.

Which Australian pharmaceutical manufacturers operate GMP HVAC facilities at scale?

CSL Limited (ASX:CSL) operates flagship manufacturing at Parkville and Broadmeadows VIC including CSL Seqirus influenza vaccine. Moderna Australia operates the mRNA facility at Monash University Clayton VIC. Pfizer Australia, GSK Australia (Boronia), Sanofi, AstraZeneca, MSD, Roche, Novartis, Eli Lilly, Janssen Cilag, Bayer and Boehringer Ingelheim operate multinational facilities. Contract manufacturers include IDT Australia (ASX:IDT) at Boronia VIC, Catalent at Braeside VIC, Apotex, Arrotex, Aspen and Viatris. Telix Pharmaceuticals (ASX:TLX) leads radiopharmaceutical theranostics. Mesoblast (ASX:MSB), Cynata, Imugene and Avita lead the cell and gene therapy sector.